Inclusion of a compound does not constitute endorsement. Information sourced from published research and regulatory filings.

CJC-1295 (no DAC)

Cat 2 → Pending Cat 1

GH Secretagogue · Research peptide (multiple suppliers)

Synthetic GHRH analog that stimulates pulsatile GH release. The no-DAC variant preserves natural GH pulsatility with a shorter duration of action.

About

Mechanism

Synthetic analog of growth hormone-releasing hormone (GHRH). Stimulates pulsatile GH release from the pituitary. The "no DAC" variant has a shorter duration and preserves natural GH pulsatility.

Half-Life

Approximately 30 minutes

Route

subcutaneous

Frequency

2-3x daily

Clinical Dosing

100-300 mcg2-3x daily

Not FDA-approved. Currently Category 2 (restricted). Pending return to Category 1. Often paired with Ipamorelin for synergistic GH release.

Dosing based on small human studies or early-phase trials. Not established by Phase 3 evidence.

Regulatory Status

FDA Category

Research peptide (FDA Category 2)

Reclassification

pending

Date Restricted

2023-09-29

Announced Return

2026-02-27

Status based on publicly available FDA communications. Verify at FDA.gov for authoritative guidance.

View full regulatory timeline →

Titration Protocols

Research Protocol

Source: Ionescu & Frohman, Journal of Clinical Endocrinology & Metabolism, 2006

Dose	Duration	Draw (2 mg vial in 2mL)	Notes
100 mcg	Maintenance	0.10 mL (10 units)	Standard dose 2-3x/day, often combined with Ipamorelin

Available Vial Sizes

2 mg

2 mg vial

5 mg

5 mg vial

Citations

[1]Pulsatile Secretion of Growth Hormone (GH) Persists during Continuous Stimulation by CJC-1295, a Long-Acting GH-Releasing Hormone Analog. Journal of Clinical Endocrinology & Metabolism, 91(12), 4792-4797. Link(Reviewed: 2026-04-16)